Madrigal Pharmaceuticals Publishes Data From Its Pre-Specified Secondary Analysis From Its Phase 3 MAESTRO-NASH Study In Journal Of Hepatology To Evaluate MASH Altered Patient Response To Rezdiffra
Citigroup Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $725
This Hedge Fund Portfolio Shrinks 17% as Billionaire Bets Big on Gold - Agnico Eagle Mines (NYSE:AEM)